News

After being revived with Naloxone in the emergency room, patients immediately enter withdrawal. Cold chills, vomiting, diarrhea – “dope sickness” is what many call it. The feeling is hard to describe, but many people who’ve experienced it or witnessed it say it’s like the worst flu times 10.

A multi-site clinical trial led by researchers at the University of Kentucky Center on Drug and Alcohol Research (CDAR) has demonstrated the effectiveness of CAM2038, a potentially transformative buprenorphine therapy for moderate-to-severe opioid use disorders.

Even with the assistance of detoxification and rehabilitation programs, 80 percent of people attempting recovery from opioid addiction will relapse.

The firm grip of opioid addiction on a person’s life necessitates sustainable therapeutic approaches proven effective through scientific trials and evidence.